Interleukin 1 Beta (Il 1Β) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Interleukin 1 Beta (Il 1Β) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Interleukin-1 beta (IL-1β) is a pro-inflammatory cytokine that plays a central role in the innate immune response and neuroinflammation. As one of the most potent inflammatory mediators, IL-1β is critically involved in the neuroinflammatory processes that contribute to neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS[@dinarello2011].
Biochemistry and Processing
IL-1β is synthesized as an inactive precursor (pro-IL-1β) that requires proteolytic cleavage to become active:
Inflammasome activation: Caspase-1 cleaves pro-IL-1β to generate mature IL-1β
NLRP3 inflammasome: Key sensor for pathogen-associated and damage-associated molecular patterns
Secretion: Active IL-1β is released through gasdermin D pores
Normal Physiological Functions
Immune Response
IL-1β is essential for host defense:
Activates endothelial cells and leukocytes
Induces fever through hypothalamic action
Stimulates acute phase protein synthesis
Promotes leukocyte recruitment[@garlanda2013]
Central Nervous System Functions
In the brain, IL-1β has physiological roles:
Modulates synaptic plasticity and memory formation
Regulates neurogenesis
Controls sleep-wake cycles
Responds to neuronal injury
Role in Neurodegenerative Diseases
Alzheimer's Disease
IL-1β is a key driver of neuroinflammation in AD:
Elevated IL-1β in AD brain tissue and CSF
Promotes [amyloid-beta](/proteins/amyloid-beta) production and aggregation
Drives [tau](/proteins/tau) hyperphosphorylation
Contributes to synaptic dysfunction[@shaftel2008]
Parkinson's Disease
IL-1β in PD:
Elevated in substantia nigra and CSF of PD patients
Contributes to dopaminergic neuron death
May initiate or accelerate disease progression
Synergizes with [alpha-synuclein](/mechanisms/alpha-synuclein) toxicity[@latter2014]
ALS
In ALS:
Increased IL-1β in motor [cortex](/brain-regions/cortex) and spinal cord
Accelerates motor neuron degeneration
Activates [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes)
Therapeutic targeting shows promise in models[@meissner2020]
Multiple Sclerosis
IL-1β promotes demyelination:
Drives Th17 cell differentiation
Activates microglia
Contributes to lesion formation
Therapeutic Targeting
IL-1β pathway inhibitors are being developed:
Anakinra: IL-1 receptor antagonist (approved for RA)
Canakinumab: Anti-IL-1β monoclonal antibody
Caspase-1 inhibitors: Block IL-1β processing
NLRP3 inflammasome inhibitors
Key Publications
Dinarello CA. (2011). Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720-3732.
Garlanda C, et al. (2013). The interleukin-1 family: back to the future. Immunity 39(6):1003-1018.
Shaftel SS, et al. (2008). The role of IL-1 in Alzheimer pathogenesis. J Neuroinflammation 5:7.
Latter EA, et al. (2014). Interleukin-1β and Parkinson's disease: a systematic review and meta-analysis. Neurology 82(10):849.
Meissner F, et al. (2020). Neuroinflammation in ALS: from mechanism to therapy. Nat Rev Neurol 16(10):581-595.
[Human Protein Atlas: IL1B](https://www.proteinatlas.org/ENSG00000125538-IL1B)
Background
The study of Interleukin 1 Beta (Il 1Β) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Dinarello CA, Interleukin-1 in the pathogenesis and treatment of inflammatory diseases (2011)](https://pubmed.ncbi.nlm.nih.gov/21406691/)
[Garlanda C, Dinarello CA, Mantovani A, The interleukin-1 family: back to the future (2013)](https://pubmed.ncbi.nlm.nih.gov/24360944/)
[Shaftel SS, Griffin WS, O'Banion MK, The role of interleukin-1 in Alzheimer disease pathogenesis (2008)](https://pubmed.ncbi.nlm.nih.gov/18275691/)
[Latter EA, Constantinescu CS, Park J, et al, Interleukin-1β and Parkinson's disease: a systematic review and meta-analysis (2014)](https://pubmed.ncbi.nlm.nih.gov/24562059/)
[Meissner F, Molawi K, Zychlinsky A, Neuroinflammation in amyotrophic lateral sclerosis: from mechanism to therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/32839585/)